Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Google fires more workers who protested its deal with IsraelTen of the world's best airports for food and drinks, according to expertsUS advances review of Nevada lithium mine amid concerns over endangered wildflowerPentagon set to send $1 billion in new military aid to Ukraine once bill clears Senate and BidenCrew members injured in crash on set of Eddie Murphy movie 'The Pickup'Child care crisis: High daycare cost hurts moms without college degreeHundreds of German police subdue 'hooligans' in training exercise for Euro 2024Lana Del Rey Coachella performance lands organizers $28K FINECanadian police charge 2 former UN employees with conspiracy to sell military equipment in LibyaI've lived in a bus stop for seven months
2.6693s , 6605.3125 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Stellar Stream news portal